Optimi Announces Non-Brokered Private Placement Optimi Announces Non-Brokered Private Placement

Optimi Health To Host MDMA Educational Quality Assurance Webinar For Clinicians And Practitioners Highlights: Optimi Chief Science and Quality Assurance experts to provide in-depth access into the Company’s safety and quality standards.Optimi experts will address critical inquiries which still...

Optimi Health Granted Precursor Licence To Formulate MDMA And Completes Encapsulation Of 40mg And 60mg Dosage Formats Optimi Health Granted Precursor Licence for 3,4-Methylenedioxyphenyl-2-propanone (“MDP2P”), the precursor used in the chemical synthesis of MDMA.